Page last updated: 2024-10-17

lactic acid and Huntington Disease

lactic acid has been researched along with Huntington Disease in 20 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's7 (35.00)18.2507
2000's5 (25.00)29.6817
2010's8 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Solís-Maldonado, M1
Miró, MP1
Acuña, AI1
Covarrubias-Pinto, A1
Loaiza, A1
Mayorga, G1
Beltrán, FA1
Cepeda, C1
Levine, MS1
Concha, II1
Bátiz, LF1
Carrasco, MA1
Castro, MA1
Steventon, JJ1
Collett, J1
Furby, H1
Hamana, K1
Foster, C1
O'Callaghan, P1
Dennis, A1
Armstrong, R1
Németh, AH1
Rosser, AE1
Murphy, K1
Quinn, L1
Busse, M1
Dawes, H1
Joshi, AS2
Singh, V1
Gahane, A1
Thakur, AK2
Gouarné, C1
Tardif, G1
Tracz, J1
Latyszenok, V1
Michaud, M1
Clemens, LE1
Yu-Taeger, L1
Nguyen, HP1
Bordet, T1
Pruss, RM1
Tsang, TM1
Haselden, JN1
Holmes, E1
Duran, R1
Barrero, FJ1
Morales, B1
Luna, JD1
Ramirez, M1
Vives, F1
Josefsen, K1
Nielsen, SM1
Campos, A1
Seifert, T1
Hasholt, L1
Nielsen, JE1
Nørremølle, A1
Skotte, NH1
Secher, NH1
Quistorff, B1
Ciammola, A1
Sassone, J1
Sciacco, M1
Mencacci, NE1
Ripolone, M1
Bizzi, C1
Colciago, C1
Moggio, M1
Parati, G1
Silani, V1
Malfatto, G1
Ryu, JK1
Kim, SU1
McLarnon, JG1
Martin, WR1
Wieler, M1
Hanstock, CC1
Jenkins, BG4
Koroshetz, WJ3
Beal, MF4
Rosen, BR3
Brouillet, E1
Chen, YC2
Storey, E1
Schulz, JB1
Kirschner, P1
Harms, L1
Meierkord, H1
Timm, G1
Pfeiffer, L1
Ludolph, AC1
Rosas, HD2
Makabe, T1
Myers, R1
MacDonald, M1
Chen, YI1
Hayden, DL1
Cudkowicz, ME1
Gårseth, M1
Sonnewald, U1
White, LR1
Rød, M1
Zwart, JA1
Nygaard, O1
Aasly, J1
Gouhier, C1
Chalon, S1
Venier-Julienne, MC1
Bodard, S1
Benoit, J1
Besnard, J1
Guilloteau, D1
Cotton, P1
Barinaga, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881]Phase 3609 participants (Actual)Interventional2008-03-31Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Behavioral Frequency Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day1.39
B - Placebo1.43

Change in Behavioral Frequency x Severity Score From Baseline to Month 60

The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day4.29
B - Placebo5.06

Change in Functional Checklist Score From Baseline to Month 60

"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-7.93
B - Placebo-8.02

Change in Independence Scale Score From Baseline to Month 60

The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Mean)
A - Coenzyme Q10 2400 mg/Day-26.30
B - Placebo-24.86

Change in Stroop Interference Test - Color Naming From Baseline to Month 60

Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-14.21
B - Placebo-14.51

Change in Stroop Interference Test - Interference From Baseline to Month 60

Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-7.57
B - Placebo-8.61

Change in Stroop Interference Test - Word Reading From Baseline to Month 60

Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-15.25
B - Placebo-19.13

Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60

The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-10.95
B - Placebo-11.36

Change in Total Functional Capacity (TFC) Score From Baseline to Month 60

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-4.53
B - Placebo-4.76

Change in Total Motor Score From Baseline to Month 60

The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day18.06
B - Placebo19.18

Change in Verbal Fluency Test From Baseline to Month 60

The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60

Interventionunits on a scale (Least Squares Mean)
A - Coenzyme Q10 2400 mg/Day-5.07
B - Placebo-4.47

Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))

The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventionrank (Mean)
A - Coenzyme Q10 2400 mg/Day303.3
B - Placebo306.7

Number Completing Study at Assigned Dosage Level

(NCT00608881)
Timeframe: 5 years

Interventionparticipants completing study on drug (Number)
A - Coenzyme Q10 2400 mg/Day98
B - Placebo108

Time to a Three-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day917
B - Placebo911

Time to a Two-Point Decline in TFC Score or Death

TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years

Interventiondays to event (Median)
A - Coenzyme Q10 2400 mg/Day553
B - Placebo549

Trials

1 trial available for lactic acid and Huntington Disease

ArticleYear
Riluzole therapy in Huntington's disease (HD).
    Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:2

    Topics: Adult; Basal Ganglia; Chorea; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease;

1999

Other Studies

19 other studies available for lactic acid and Huntington Disease

ArticleYear
Altered lactate metabolism in Huntington's disease is dependent on GLUT3 expression.
    CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:4

    Topics: Animals; Cell Line; Corpus Striatum; Disease Models, Animal; Female; Glucose Transporter Type 3; Hum

2018
Alterations in the metabolic and cardiorespiratory response to exercise in Huntington's Disease.
    Parkinsonism & related disorders, 2018, Volume: 54

    Topics: Adult; Aged; Exercise; Female; Heart Rate; Humans; Huntington Disease; Lactic Acid; Male; Middle Age

2018
Biodegradable Nanoparticles Containing Mechanism Based Peptide Inhibitors Reduce Polyglutamine Aggregation in Cell Models and Alleviate Motor Symptoms in a Drosophila Model of Huntington's Disease.
    ACS chemical neuroscience, 2019, 03-20, Volume: 10, Issue:3

    Topics: Animals; Blood-Brain Barrier; Brain; Cell Aggregation; Disease Models, Animal; Drosophila; Huntingto

2019
Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Animals; Cell Respiration; Corpus Striatum; Disease Models, Animal; Extracellular Space; Glucose; Gl

2013
Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease.
    Journal of peptide science : an official publication of the European Peptide Society, 2014, Volume: 20, Issue:8

    Topics: Blood-Brain Barrier; Humans; Huntingtin Protein; Huntington Disease; Lactic Acid; Nanoparticles; Ner

2014
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
    Neurochemical research, 2009, Volume: 34, Issue:7

    Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum;

2009
Oxidative stress and plasma aminopeptidase activity in Huntington's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:3

    Topics: Adult; Aminopeptidases; Female; Heterozygote; Humans; Huntington Disease; Lactic Acid; Lipid Peroxid

2010
Reduced gluconeogenesis and lactate clearance in Huntington's disease.
    Neurobiology of disease, 2010, Volume: 40, Issue:3

    Topics: Animals; Blood Glucose; Blotting, Western; Brain; Exercise; Exercise Test; Female; Gluconeogenesis;

2010
Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:1

    Topics: Adult; Aged; Anaerobic Threshold; Analysis of Variance; Cells, Cultured; Female; Heart; Humans; Hunt

2011
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
    Experimental neurology, 2004, Volume: 187, Issue:1

    Topics: Animals; Disease Models, Animal; Drug Administration Routes; Enzyme Inhibitors; Guanidines; Huntingt

2004
Is brain lactate increased in Huntington's disease?
    Journal of the neurological sciences, 2007, Dec-15, Volume: 263, Issue:1-2

    Topics: Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Humans; Huntington Dis

2007
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.
    Neurology, 1993, Volume: 43, Issue:12

    Topics: Adult; Aspartic Acid; Basal Ganglia; Choline; Creatine; Energy Metabolism; Female; Humans; Huntingto

1993
Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1996, Volume: 16, Issue:3

    Topics: Aging; Animals; Aspartic Acid; Electron Transport Complex II; Energy Metabolism; Huntington Disease;

1996
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study.
    Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 62, Issue:1

    Topics: Adult; Aged; Aspartic Acid; Choline; Female; Frontal Lobe; Humans; Huntington Disease; Lactic Acid;

1997
1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.
    Neurology, 1998, Volume: 50, Issue:5

    Topics: Adult; Brain; Case-Control Studies; Corpus Striatum; Energy Metabolism; Female; Humans; Huntington D

1998
Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease.
    Journal of neuroscience research, 2000, Jun-15, Volume: 60, Issue:6

    Topics: Adult; Aged; Citric Acid; Energy Metabolism; Female; Humans; Huntington Disease; Lactic Acid; Magnet

2000
Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide.
    Neuroscience letters, 2000, Jul-07, Volume: 288, Issue:1

    Topics: Animals; Antineoplastic Agents; Autoradiography; Benzamides; Biocompatible Materials; Corpus Striatu

2000
Neuroscientists begin to piece together more parts of Huntington's disease puzzle.
    JAMA, 1992, Dec-16, Volume: 268, Issue:23

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Biomarkers; Brain Chemistry; Dise

1992
Neuroscience fantasia in an appropriate setting.
    Science (New York, N.Y.), 1992, Nov-06, Volume: 258, Issue:5084

    Topics: Cilia; Hair Cells, Auditory; Hearing; Humans; Huntington Disease; Lactates; Lactic Acid; Neuroscienc

1992